GB1555197A - Process for the isolation of a placentaspecificglycoprotein - Google Patents

Process for the isolation of a placentaspecificglycoprotein

Info

Publication number
GB1555197A
GB1555197A GB15778/77A GB1577877A GB1555197A GB 1555197 A GB1555197 A GB 1555197A GB 15778/77 A GB15778/77 A GB 15778/77A GB 1577877 A GB1577877 A GB 1577877A GB 1555197 A GB1555197 A GB 1555197A
Authority
GB
United Kingdom
Prior art keywords
support
bound
order
solution
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB15778/77A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of GB1555197A publication Critical patent/GB1555197A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

In order to concentrate the placenta-specific protein PP5, a PP5-containing protein solution is brought into contact, at a pH of between 4 and 9, with an antibody against PP5 which is bound to an insoluble support. The support with the PP5 bound to it is separated off from the liquid phase. In order to release the PP5, this support is treated with an aqueous medium of a pH of from 2 to 4, or with a solution of a substance which dissociates protein bonds at a pH of from 4 to 9. The PP5 which is obtained can be used in a diagnostic agent for detecting PP5 and antibodies directed against PP5.
GB15778/77A 1976-04-17 1977-04-15 Process for the isolation of a placentaspecificglycoprotein Expired GB1555197A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2616984A DE2616984C3 (en) 1976-04-17 1976-04-17 Method for the isolation and purification of a placenta-specific glycoprotein

Publications (1)

Publication Number Publication Date
GB1555197A true GB1555197A (en) 1979-11-07

Family

ID=5975638

Family Applications (1)

Application Number Title Priority Date Filing Date
GB15778/77A Expired GB1555197A (en) 1976-04-17 1977-04-15 Process for the isolation of a placentaspecificglycoprotein

Country Status (20)

Country Link
JP (1) JPS52154509A (en)
AT (1) AT362057B (en)
AU (1) AU517434B2 (en)
BE (1) BE853711A (en)
CA (1) CA1101847A (en)
CH (2) CH630643A5 (en)
DE (1) DE2616984C3 (en)
DK (1) DK168577A (en)
ES (2) ES457714A1 (en)
FI (1) FI60875C (en)
FR (1) FR2348222A1 (en)
GB (1) GB1555197A (en)
IE (1) IE44824B1 (en)
IL (1) IL51883A (en)
IT (1) IT1075832B (en)
LU (1) LU77143A1 (en)
NL (1) NL7703963A (en)
NO (1) NO146747C (en)
NZ (1) NZ183878A (en)
SE (1) SE7704359L (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368148A (en) 1980-01-10 1983-01-11 Behringwerke Aktiengesellschaft Protein PP9, process for its enrichment and its isolation and its use
US6171577B1 (en) 1994-01-24 2001-01-09 Neorx Corporation Radiolabeled annexins
US7115248B2 (en) 1994-01-24 2006-10-03 Neorx Corporation Radiolabeled annexins

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2640387C3 (en) * 1976-09-08 1981-01-22 Behringwerke Ag, 3550 Marburg Tissue-specific protein and method for its production
DE2720704C2 (en) * 1977-05-07 1986-09-25 Behringwerke Ag, 3550 Marburg New glycoprotein, process for its production and its uses
DE2745680A1 (en) * 1977-10-11 1979-04-12 Behringwerke Ag CONTRACEPTIVE MEANS
EP0029893B1 (en) * 1979-11-02 1987-05-20 Karl Prof. Dr. Theurer Process for concentration of tumor-inhibiting substances
DE3334405A1 (en) * 1983-09-23 1985-04-04 Behringwerke Ag, 3550 Marburg MEMBRANE ASSOCIATED PROTEINS (MP (DOWN ARROW) 2 (DOWN ARROW)), METHOD FOR THEIR EXTRACTION AND USE
NZ212523A (en) * 1985-06-24 1989-01-06 Univ Massey Mobile phase for purification of proteins by high performance liquid chromatography
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4368148A (en) 1980-01-10 1983-01-11 Behringwerke Aktiengesellschaft Protein PP9, process for its enrichment and its isolation and its use
US6171577B1 (en) 1994-01-24 2001-01-09 Neorx Corporation Radiolabeled annexins
US7115248B2 (en) 1994-01-24 2006-10-03 Neorx Corporation Radiolabeled annexins
US7744853B2 (en) 1996-07-26 2010-06-29 Poniard Pharmaceuticals, Inc. Radiolabeled annexins

Also Published As

Publication number Publication date
NZ183878A (en) 1980-04-28
DE2616984B2 (en) 1981-01-29
ES457714A1 (en) 1978-02-16
NO146747B (en) 1982-08-23
IL51883A (en) 1980-02-29
NO771316L (en) 1977-10-18
IE44824B1 (en) 1982-04-07
AT362057B (en) 1981-04-27
FI60875C (en) 1982-04-13
DE2616984C3 (en) 1981-10-29
FR2348222B1 (en) 1980-02-08
IE44824L (en) 1977-10-17
CH630643A5 (en) 1982-06-30
ATA266377A (en) 1980-09-15
JPS52154509A (en) 1977-12-22
SE7704359L (en) 1977-10-18
DE2616984A1 (en) 1977-10-20
FI60875B (en) 1981-12-31
IL51883A0 (en) 1977-06-30
AU517434B2 (en) 1981-07-30
NL7703963A (en) 1977-10-19
FR2348222A1 (en) 1977-11-10
IT1075832B (en) 1985-04-22
FI771186A (en) 1977-10-18
ES462699A1 (en) 1978-07-01
CH632091A5 (en) 1982-09-15
CA1101847A (en) 1981-05-26
NO146747C (en) 1982-12-01
BE853711A (en) 1977-10-18
LU77143A1 (en) 1977-11-14
DK168577A (en) 1977-10-18
AU2431977A (en) 1978-10-19

Similar Documents

Publication Publication Date Title
DK96689D0 (en) IMMUNE DETERMINATION AND DIAGNOSTIC METHOD FOR USING THE PROCEDURE
DK97189A (en) immobilization
ES398372A1 (en) Process for the detection and determination of specific binding proteins and their corresponding bindable substances
GB1555197A (en) Process for the isolation of a placentaspecificglycoprotein
ES454276A1 (en) Pregnancy test device
AU8317482A (en) Assay of antibodies to soluble antigens
NO881904D0 (en) PROCEDURE FOR SELECTIVE IMMUNOLOGICAL DETERMINATION OF INTACT PROCOLLAGEN PEPTID (TYPE III) AND PROCOLLAGEN (TYPE III) IN BODY LIQUID, AND AGENT FOR ITS IMPLEMENTATION.
Stevens et al. Immunochemical and electrophoretic properties of oestrous rabbit uterine fluid proteins obtained by uterine ligation
DK256387A (en) IMMUNE DETERMINATION METHOD AND EQUIPMENT
ES2018179B3 (en) PROCEDURE AND REAGENT FOR THE DETERMINATION OF THE TOTAL AMOUNT OF BILIRRUBINE.
ATE124706T1 (en) METHOD FOR ISOLATION OF BASAL MEMBRANE PROTEINS FROM HUMAN AND ANIMAL TISSUES.
AU1994788A (en) Method for the diagnosis of infections with detection of lipopolysaccharide antigens
GB1151608A (en) A Method for Determining Vitamin B12
JPS55141452A (en) Synthetic polypeptide
GB2007362A (en) Method of preparing a device for use in immunoassay
FR2385099A1 (en) Rapid determn. of antigens and antibodies - by marking with enzyme, complex formation on a support and acid elution
MY103043A (en) Swine dysentery vaccine
AU1102588A (en) Diagnostic test for swine dysentery
ES446939A1 (en) Process for the enrichment of pregnancy specific -glycoprrotein
GB1356503A (en) Diagnostic method and means therefor
ES2002578A6 (en) A process for the preparation of diagnostic reagents.
JPS5347517A (en) Immobilized antibody membrane for antigen protein determinationmethod and its apparatus
FR2324005A1 (en) Analytical method, esp. for thyroxine, using proteolytic enzyme - to release active component from binding protein
KR860008779A (en) Method for producing antibody forming compound

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee